Fresh insight is shed on the mechanisms behind clear cell Renal Cell Carcinoma (ccRCC) development by a new study. The findings of the study are published in the journal eLife.
The study in human cells and mice could have implications for how we understand and treat ccRCC a major subtype of human kidney cancer.
‘Kidney cancer is one of the leading causes of death in both men and women. A new study suggests activation of ISGF3 protein could be a novel therapeutic approach for patients with clear cell renal cancer.’
Kidney cancer is one of the top 10 causes of death from cancer in both men and women. Inactivation of the tumor suppressor gene VHL is the primary cause of ccRCC, which is the most frequently occurring subtype of the disease.
Tumour suppressor genes slow down cell division, repair DNA mistakes, and tell cells when to die. Mutations or inactivation of these genes stop them from working properly, which can lead to uncontrolled cell growth and cancer development.
"The disabling of VHL is usually followed by mutations in other tumor suppressor genes that are involved in ccRCC, such as PBRM1 and KDM5C," says co-first author Lili Liao, Postdoctoral Fellow at Jefferson (Philadelphia University + Thomas Jefferson University) and researcher at the Sidney Kimmel Cancer Center - Jefferson Health, Philadelphia, US. "These secondary tumor suppressors each have their own unique functions, and their mutations are associated with different survival risks, yet they all collaborate with VHL loss to promote cancer development. In this study, we wanted to investigate whether they share a common tumor suppressor pathway that might be implicated in future ccRCC treatment."
While probing the gene expression patterns (the processes whereby instructions within DNA are converted into messenger RNA), the research team found that VHL, PBRM1, KDM5C, SETD2, and BAP1 all regulate the interferon-stimulated gene factor 3 (ISGF3) - a master regulator that is key to viral infection response.
"We also saw that ISGF3 is strongly tumor-suppressive in a xenograft mouse model of ccRCC, as its loss enables tumors to increase significantly in size," explains co-senior author Haifeng Yang, Assistant Professor at Jefferson and researcher at the Sidney Kimmel Cancer Center - Jefferson Health. "Conversely, boosting ISGF3 in human ccRCC cancer cells shrinks the tumors they form into tiny nodules."
After VHL inactivation, it is known that the hypoxia-inducible factor (HIF)2 alpha becomes constantly active. HIFs respond to decreases in oxygen levels available within cellular environments. "We found that HIF2 alpha triggers the activation of ISGF3, which acts as a brake for tumour growth," Yang continues. "This brake can be disabled by the loss of any of the secondary tumor suppressors, suggesting that this is a key negative feedback loop in ccRCC."
"It is surprising to see that so many major tumor suppressor genes in ccRCC share the same target in ISGF3," adds co-senior author Qin Yan, Associate Professor of Pathology at Yale University, Connecticut, US. "As many critical cancer genes in kidney cancer converge on ISGF3, it might play significant roles in drug development, patient responses to treatments, and survival."
"There is a significant unmet clinical need to develop new strategies for treating ccRCC. Dr. Yang's breakthrough study brings us one step closer to this goal," concludes Dr. Karen E. Knudsen, Enterprise Director of the Sidney Kimmel Cancer Center at Jefferson Health.